Analgesic prescribing in patients with inflammatory arthritis in England : an observational study using electronic healthcare record data
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVES: International data suggest inflammatory arthritis (IA) pain management frequently involves opioid prescribing, despite little evidence of efficacy, and potential harms. We evaluated analgesic prescribing in English National Health Service-managed patients with IA.
METHODS: Repeated cross-sectional analyses in the Consultations in Primary Care Archive (primary care consultation and prescription data in nine general practices from 2000 to 2015) evaluated the annual prevalence of analgesic prescriptions in: (i) IA cases (RA, PsA or axial spondyloarthritis [SpA]), and (ii) up to five age-, sex- and practice-matched controls. Analgesic prescriptions were classified into basic, opioids, gabapentinoids and oral NSAIDs, and sub-classified into chronic and intermittent (≥3 and 1-2 prescriptions per calendar year, respectively).
RESULTS: In 2000, there were 594 cases and 2652 controls, rising to 1080 cases and 4703 controls in 2015. In all years, most (65.3-78.5%) cases received analgesics, compared with fewer (37.5-41.1%) controls. Opioid prescribing in cases fell between 2000 and 2015 but remained common with 45.4% (95% CI: 42.4%, 48.4%) and 32.9% (95% CI: 29.8%, 36.0%) receiving at least 1 and ≥3 opioid prescriptions, respectively, in 2015. Gabapentinoid prescription prevalence in cases increased from 0% in 2000 to 9.5% (95% CI: 7.9%, 11.4%) in 2015, and oral NSAID prescription prevalence fell from 53.7% (95% CI: 49.6%, 57.8%) in 2000 to 25.0% (95% CI: 22.4%, 27.7%) in 2015. Across years, analgesic prescribing was commoner in RA than PsA/axial SpA, and 1.7-2.0 times higher in cases than controls.
CONCLUSIONS: Analgesic prescribing in IA is common. This is at variance with existing evidence of analgesic efficacy and risks, and guidelines. Interventions are needed to improve analgesic prescribing in this population.
| Errataetall: |
CommentIn: Rheumatology (Oxford). 2022 Aug 3;61(8):3099-3100. - PMID 35266514 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), 8 vom: 03. Aug., Seite 3201-3211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scott, Ian C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics |
|---|
| Anmerkungen: |
Date Completed 05.08.2022 Date Revised 17.08.2022 published: Print CommentIn: Rheumatology (Oxford). 2022 Aug 3;61(8):3099-3100. - PMID 35266514 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keab870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333865219 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333865219 | ||
| 003 | DE-627 | ||
| 005 | 20231225222525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keab870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333865219 | ||
| 035 | |a (NLM)34849617 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scott, Ian C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analgesic prescribing in patients with inflammatory arthritis in England |b an observational study using electronic healthcare record data |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2022 | ||
| 500 | |a Date Revised 17.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Rheumatology (Oxford). 2022 Aug 3;61(8):3099-3100. - PMID 35266514 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a OBJECTIVES: International data suggest inflammatory arthritis (IA) pain management frequently involves opioid prescribing, despite little evidence of efficacy, and potential harms. We evaluated analgesic prescribing in English National Health Service-managed patients with IA | ||
| 520 | |a METHODS: Repeated cross-sectional analyses in the Consultations in Primary Care Archive (primary care consultation and prescription data in nine general practices from 2000 to 2015) evaluated the annual prevalence of analgesic prescriptions in: (i) IA cases (RA, PsA or axial spondyloarthritis [SpA]), and (ii) up to five age-, sex- and practice-matched controls. Analgesic prescriptions were classified into basic, opioids, gabapentinoids and oral NSAIDs, and sub-classified into chronic and intermittent (≥3 and 1-2 prescriptions per calendar year, respectively) | ||
| 520 | |a RESULTS: In 2000, there were 594 cases and 2652 controls, rising to 1080 cases and 4703 controls in 2015. In all years, most (65.3-78.5%) cases received analgesics, compared with fewer (37.5-41.1%) controls. Opioid prescribing in cases fell between 2000 and 2015 but remained common with 45.4% (95% CI: 42.4%, 48.4%) and 32.9% (95% CI: 29.8%, 36.0%) receiving at least 1 and ≥3 opioid prescriptions, respectively, in 2015. Gabapentinoid prescription prevalence in cases increased from 0% in 2000 to 9.5% (95% CI: 7.9%, 11.4%) in 2015, and oral NSAID prescription prevalence fell from 53.7% (95% CI: 49.6%, 57.8%) in 2000 to 25.0% (95% CI: 22.4%, 27.7%) in 2015. Across years, analgesic prescribing was commoner in RA than PsA/axial SpA, and 1.7-2.0 times higher in cases than controls | ||
| 520 | |a CONCLUSIONS: Analgesic prescribing in IA is common. This is at variance with existing evidence of analgesic efficacy and risks, and guidelines. Interventions are needed to improve analgesic prescribing in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a analgesics | |
| 650 | 4 | |a inflammatory arthritis | |
| 650 | 4 | |a opioids | |
| 650 | 4 | |a pain | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 700 | 1 | |a Bailey, James |e verfasserin |4 aut | |
| 700 | 1 | |a White, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Mallen, Christian D |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Sara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), 8 vom: 03. Aug., Seite 3201-3211 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:8 |g day:03 |g month:08 |g pages:3201-3211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keab870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 8 |b 03 |c 08 |h 3201-3211 | ||